This website uses cookies
Read our Privacy policy and Terms of use for more information.
Long Form Content
Apr 21, 2026
•
4 min read
🧬 Eli Lilly acquires Kelonia Therapeutics for up to $7B to expand in vivo CAR-T capabilities, AstraZeneca's (tozorakimab) meets primary endpoint in Ph3 trial for chronic obstructive pulmonary disease, Biogen + TJ Biopharma expand partnership for China rights to felzartamab - $100M upfront + $850M biobucks
Apr 20, 2026
3 min read
🧬 Former Genentech leader unveils Synthetic Design Lab - developing adaptive "smart" ADC cancer drugs, UCB to acquire Neurona Therapeutics for up to $1.2B - expanding into seizure cell therapy, Merck & Co. unveils Ph1/Ph2 data for MK-2010 (MK-2010) - PD-1xVEGF bispecific in non-small cell lung cancer
Apr 18, 2026
🧬 From policy to production: how China is scaling synthetic biology - and what it means for global competition
Apr 17, 2026
🧬 Kailera Therapeutics prices massive $625M IPO for advancing next-generation obesity care treatments, Roche launches new Phase III study to pursue EU approval for DMD gene therapy Elevidys, Aligos Therapeutics + Amoytop ink $445M deal licensing HBV drug pevifoscorvir sodium China rights
Apr 16, 2026
🧬 Spain plans $200M VC fund bridging Spanish biotechs with Boston's life science ecosystem, Beeline Medicines debuts with $300M Series A - licensing five Bristol Myers immune disease drug candidates, Sandoz signs manufacturing and supply agreement with Rwanda government to provide critical medicines across Africa
Apr 15, 2026
8 min read
🧬 Novo Nordisk + OpenAI partner to integrate AI across drug discovery + manufacturing + corporate operations, Amazon Web Services launches Amazon Bio Discovery AI tool to accelerate antibody design and drug discovery, Eli Lilly acquires CrossBridge Bio for up to $300M to advance dual-payload ADC cancer pipeline, Alamar Biosciences files for $159M IPO - protein sequencing and biomarker profiling tools, Harbinger Health raises $100M to develop RESOLVE multi-cancer liquid biopsy detection tests
Apr 14, 2026
🧬 Kailera plans $528.5M IPO to advance quartet of Chinese obesity assets, Eli Lilly's Jaypirca hits Ph3 endpoint for chronic lymphocytic leukemia in fixed-duration combination therapy, AbbVie + Haisco Pharmaceutical partner on pain compounds development - up to $715M deal value
Apr 13, 2026
7 min read
🧬 Sun Pharma readies $12B binding offer to acquire women's health company Organon amid competing bids, Vivatides Therapeutics raises $54M Series A for RNA delivery beyond the liver, GSK advances mocertatug rezetecan (Mo-Rez) targeting B7-H4 to Ph3 trials for ovarian and endometrial cancers
Apr 11, 2026
24 min read
Why the biotech of the future might be a lot smaller and a lot more nimble
Apr 10, 2026
🧬 Eli Lilly launches obesity pill Foundayo at $149 - intensifying GLP-1 competition with Novo Nordisk's Wegovy, Genentech receives FDA approval for updated Vabysmo (faricimab-svoa) label extending macular edema treatment beyond six months, Avalyn Pharma plans IPO - developing inhalable IPF treatments for lung disease, Invivyd prepares VMS063 antibody targeting fusion protein for Ph1 testing in measles treatment and prevention, Boehringer Ingelheim hands Click Therapeutics marketing rights to schizophrenia PDT CT-155 + $50M investment
Apr 9, 2026
🧬 Jeito Capital raises $1.2B fund - investing in European clinical-stage drugmakers, Shionogi lands US BARDA contract for Fetroja antibiotic manufacturing - $482M potential value, Gilead Sciences pauses M&A after acquiring Arcellx + Ouro Medicines + and Tubulis within six weeks
Apr 8, 2026
🧬 Gilead Sciences to acquire German biotech Tubulis for $3.1B upfront in ADC deal, E2 raises $80M Series C for next-gen thrombectomy treatment commercialization, Vertex Pharmaceuticals + Halozyme partner on Hypercon drug delivery technology - $15M upfront plus milestones
